Table 2.
Patient demographical characteristics of 68 multiple primary patients with hepatocellular carcinoma
| Characteristic | Total | Synchronous group (n = 22) | Metachronous group (n = 46) | P value * |
|---|---|---|---|---|
| Age (years) † |
|
|
|
|
| < 58 b |
33 |
8 |
25 |
0.165 |
| ≥ 58 |
35 |
14 |
21 |
|
| Gender |
|
|
|
0.514 |
| Male |
61 |
21 |
40 |
|
| Female |
7 |
1 |
6 |
|
| HBsAg status |
|
|
|
0.393 |
| Negative |
23 |
9 |
14 |
|
| Positive |
45 |
13 |
32 |
|
| Serum AFP level (ng/ml) |
|
|
|
0.085 |
| < 25 |
30 |
13 |
17 |
|
| ≥ 25 |
38 |
9 |
29 |
|
| Serum GGT level (U/ml) |
|
|
|
0.181 |
| < 50 |
23 |
5 |
18 |
|
| ≥ 50 |
45 |
17 |
28 |
|
| Child-Pugh classification |
|
|
|
0.932 |
| A |
49 |
16 |
33 |
|
| B |
19 |
6 |
13 |
|
| TNM stage |
|
|
|
0.735 |
| I |
43 |
14 |
29 |
|
| II |
9 |
2 |
7 |
|
| III |
16 |
6 |
10 |
|
| Treatment for HCC |
|
|
|
0.309 |
| Resection |
35 |
9 |
26 |
|
| Ablation |
7 |
3 |
4 |
|
| TACE |
14 |
4 |
10 |
|
| Supportive |
11 |
6 |
5 |
|
| Treatment for extrahepatic cancer |
|
|
<0.001 |
|
| Curative |
54 |
12 |
42 |
|
| Palliative |
8 |
4 |
4 |
|
| Supportive | 6 | 6 | 0 | |
HCC hepatocellular carcinoma, HbsAg Hepatitis B surface Antigen, AFP α-fetoprotein, GGT gamma-glutamyltransferase, TNM tumor-node-metastasis, TACE transarterial chemoembolization.
* Chi-square or Fisher’s exact test.
† Patients were divided according to the median age.